• Globe Newswire

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Globenewswire -

• Globe Newswire

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Globenewswire -

• Globe Newswire

Casey House creates fictitious drug, Stigmavir, to smash HIV stigma within the health care system

• Globe Newswire

Statement by SBA Administrator Guzman on President Biden’s

Washington D.C., March 02, 2023 (GLOBE NEWSWIRE) -- Today, Administrator Isabella Casillas Guzman, head of the U.S. Small Business Administration (SBA)...